VX-264

N/A

Report date: 2025/06/13 20:00:59

Base Information

Drug NameVX-264
Drug Alias NameVX-264
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Pancreatic islet cell therapyCell and gene therapy > Cell therapy > Source of cells > Stem cells-derivedCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionPancreatic beta cell replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesLonzaVertex Pharmaceuticals Incorporated
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A